Post by AZAFAROS B.V.

AZAFAROS B.V. is delighted to announce the promotion of Dominique Nijkamp to Chief Clinical Development Officer. The move comes at a crucial stage in the development of our lead asset in rare disease patients and highlights the need for strong leadership as we investigate #nizubaglustat through two pivotal Phase 3 (#NAVIGATE) studies in #GM1 and #GM2 Gangliosidoses and Niemann-Pick type C disease (#NPC). “The promotion recognises Dominique’s significant contributions to Azafaros and her increasing responsibilities as our clinical pipeline continues to grow,” said Stefano Portolano, MD, CEO at Azafaros.  “It also reflects the evolution of our organization as we continue to mature on our path toward becoming a leading European rare disease company. In her new role, Dominique will continue to lead and strengthen our clinical development organization as we expand our programs and capabilities.” #clinicaldevelopment, #leadership, #promotion, #raredisease, #GM1, #GM2, #NPC